Bangkok, December 4th 2014
Austrianova reports that it has officially opened its’ office, lab and GMP facility at Thailand Science Park, Bangkok. The opening ceremony, held last week, included scientific presentations and a site visit of the custom built facility. Attendees included representatives from the Thailand Science Park management, the Thai National Science and Technology Development Agency and the Thailand Center of Excellence for Life Sciences (TCELS) as well as guests of honour Kenneth L. Waggoner (CEO) and Gerald C. Crabtree (COO) of Nuvilex Inc., and various other Austrianova partners and friends including the Austrian Trade Commission, Betagro, CDIP, Erber AG, Siricell, Mahidol University, King Mongkut’s University of Technology Thonburi and the team from Austrianova Singapore plus some key investors in Austrianova.
Brian Salmons, CEO of Austrianova, stated “As well as being pleased to officially open our Thai facility, we were happy to see so many friends and partners as well as various supporters of our endeavours. Our new facility includes a unique, state-of-the-art and custom-built, controlled environment isolator for cell production, which we believe to be the first in Asia. This isolator system, housed in a newly built conventional Class D cleanroom, will ensure that all Cell-in-a-Box® products are manufactured according to the highest international pharmaceutical production standards”. Walter H. Gunzburg, Chairman of Austrianova, said ““We have worked closely with TCELS to develop this world-first encapsulated cell production and research facility. This allows Austrianova to produce Cell-in-a-Box® encapsulated cell products for partners such as Nuvilex, Inc. as well as other key partners. We would like to thank all of our friends for making the opening ceremony such a great success”.
About Austrianova:
Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.
Help employers find you! Check out all the jobs and post your resume.
